Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases

Melanoma and Skin Cancer

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

N Engl J Med.

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators

doi: 10.1056/NEJMoa1709030.

Melanoma and Skin Cancer

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

N Engl J Med.

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM

doi: 10.1056/NEJMoa1708539.

Melanoma and Skin Cancer

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

Eur J Cancer

Weber JS, Ascierto PA, Middleton MR, Hennicken D, Zoffoli R, Pieters A, Amadi A, Kupas K, Kotapati S, Moshyk A, Schadendorf D

doi: 10.1016/j.ejca.2021.08.028

Melanoma and Skin Cancer

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial

Lancet.

Utjés D, Malmstedt J, Teras J, Drzewiecki K, Gullestad HP, Ingvar C, Eriksson H, Gillgren P

doi: 10.1016/S0140-6736(19)31132-8.

Melanoma and Skin Cancer

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Eur J Cancer

Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

doi: 10.1016/j.ejca.2021.09.023

Melanoma and Skin Cancer

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival

JAMA Dermatol.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C, for MelBase.

doi: 10.1001/jamadermatol.

Psoriatic Arthritis

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Rheumatol Int.

Deza G, Notario J, Ferran M, Beltrán E, Almirall M, Alcalá R, Ruiz-Carrascosa JC, Sánchez R, Pérez S, García-Vivar ML, Galíndez E, Mora M, Rodríguez J, Gallardo F

doi: 10.1007/s00296-018-4144-8.

Melanoma and Skin Cancer

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Melanoma Res.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ

doi: 10.1097/CMR.

Melanoma and Skin Cancer

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma

Melanoma Res

Marcaillou M, Linder C, Chaltiel L, Sibaud V, Pagès C, Modesto A, Chira C, Dalmasso C, Boulinguez S, Bedane C, Meyer N

doi: 10.1097/CMR.0000000000000700

Related content

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival

Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma